Eli Lilly SG&A Expenses 2012-2026 | LLY

Eli Lilly sg&a expenses for the twelve months ending March 31, 2026 were $11.559B, a 26.88% increase year-over-year.

  • Eli Lilly annual sg&a expenses for 2025 were $11.094B, a 29.09% increase from 2024.
  • Eli Lilly annual sg&a expenses for 2024 were $8.594B, a 16.08% increase from 2023.
  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.

Eli Lilly SG&A Expenses 2012-2026 | LLY

  • Eli Lilly annual sg&a expenses for 2025 were $11.094B, a 29.09% increase from 2024.
  • Eli Lilly annual sg&a expenses for 2024 were $8.594B, a 16.08% increase from 2023.
  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B